AQST - Aquestive Therapeutics, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

AQST

AQUESTIVE THERAPEUTICS, INC.

NASDAQ

$4.57

▲ UP 0.44% (0.02)

KEY STATISTICS

Market Cap$572.32 M

52w High$7.55

52w Low$2.93

Dividend Yield—

Frequency—

P/E-7.03

Volume1.09M

Shares Out.125.47M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Daniel Barber

COMPENSATION 2026

Salary$659,885

Stock Awards$1,547,342

Incentive Plan Pay$409,132

All Other Comp.$0

Total$3,493,559

ABOUT

SECTOR

Healthcare

WENT PUBLIC

July 25, 2018

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

147

PRICE TARGET

Target High$11.00

Target Low$11.00

Target Median$11.00

Target Consensus$11.00

UPCOMING EARNINGS

DateNov 4, 2026

DayWednesday

Rev. Est.$11.02M

NOV

WED

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

37.03%

HOLDERS

262

TOP 8 OF 262 · RANKED BY POSITION SIZE

Bratton Capital Management, L.P.

Perceptive Advisors LLC

3.8M sh

$21.02M

Federated Hermes, Inc.

PRICE

$4.57 ▲ UP 0.44% (+$0.02)

About Aquestive Therapeutics, Inc.

https://www.aquestive.com ↗

Aquestive Therapeutics develops and markets innovative oral film products for neurological, psychiatric, and other medical conditions, with a pipeline of proprietary formulations targeting unmet needs globally.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT AQUESTIVE THERAPEUTICS, INC. IS KNOWN FOR

Anaphylm™ (epinephrine) Sublingual Film

Anaphylm™ is a late-stage, sublingual epinephrine film for emergency allergic reactions, offering a less invasive alternative to injections, with FDA approval efforts ongoing despite prior regulatory challenges.

COMPETITORS

COMPETITOR

Aquestive Therapeutics in 2025

SENTIMENT: − NEGATIVE

REGULATORY · JANUARY 2026

Aquestive Therapeutics Stock Plummets After FDA Cites Deficiencies in New Drug Application for Anaphylm

Aquestive Therapeutics' stock price experienced a dramatic premarket drop of approximately 48% on January 9, 2026, after the company announced that the U.S. Food and Drug Administration (FDA) had identified deficiencies in its New Drug Application (NDA) for Anaphylm. The FDA's letter stated that these deficiencies would preclude discussions on labeling and post-marketing commitments at that time, creating significant uncertainty around the approval of the company's key product candidate. This news generated substantial media coverage and investor concern, overshadowing other company developments in 2025.

MARKET EXPANSION · THROUGHOUT 2025 · IN PROGRESS

Aquestive Therapeutics Goes All-In on Anaphylm™ with Global Launch Preparations and Strategic Financing

In 2025, Aquestive Therapeutics made a pivotal strategic shift to prioritize the global commercialization of its lead product candidate, Anaphylm™, an orally administered epinephrine film for severe allergic reactions. This included submitting a New Drug Application (NDA) to the U.S. FDA, initiating regulatory processes in Canada, Europe, and the United Kingdom, and securing significant funding to support a potential 2026 launch.

Latest News

GLOBENEWSWIRE · SEP 29, 2026

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Rich Daly to the Company's Board of Directors, effective October 14, 2026.

READ ARTICLE